(11) 98705-3426
TrademarkIQ iconTrademarkIQ
Back to search
Official data from INPI

MÉTODOS DE USO DE INIBIDORES DA ALDOSTERONA SINTASE

Em AnáliseInvention PatentPCT · US2022073148

Application data

Invention Patent MÉTODOS DE USO DE INIBIDORES DA ALDOSTERONA SINTASE de CINCOR PHARMA, INC. — IPC A61K 31/4725
Invention Patent MÉTODOS DE USO DE INIBIDORES DA ALDOSTERONA SINTASE de CINCOR PHARMA, INC. — IPC A61K 31/4725. Drawing published by the INPI in the Industrial Property Gazette.

Number

112023027025

Type

Invention Patent

Filing

06/24/2022

Publication

03/12/2024

PCT

US2022073148

Progress at the INPI

  1. Filing06/24/22
  2. Publication
  3. Examination
  4. Allowance
  5. Grant
  6. In force

The application was filed at the INPI on 06/24/2022. It awaits formal examination and publication in the RPI gazette.

Leave your contact and we will alert you

We track INPI publications and let you know as soon as this case moves.

We use your details only for this alert.

Latest action published by the INPI: 03/12/2024. We update with every new RPI gazette, published weekly.

Applicants and inventors

Applicants

CINCOR PHARMA, INC.

US

Inventors

B. M. (pessoa física)

US

C. P. (pessoa física)

US

M. B. (pessoa física)

US

Technical data

Priority claims

US

63/214,521 · 06/24/2021

US

63/290,364 · 12/16/2021

Abstract

MÉTODOS DE USO DE INIBIDORES DA ALDOSTERONA SINTASE.A presente invenção refere-se a métodos para inibir a aldosterona sintase humana, tratar hipertensão ou tratar aldosteronismo primário em um sujeito com necessidade do mesmo, compreendendo a administração de uma quantidade eficaz do (R)-Composto 1 ao sujeito, em que (R)-Composto 1 é: Fórmula (I). (I)

Prosecution history

Publications in the Brazilian Industrial Property Gazette (RPI).

Notificação de entrada na fase nacional - PCT

#1.3

03/12/2024

RPI 2775

Alteração de dados cadastrais

#1.1

01/02/2024

RPI 2765

Patent monitoring

Track this patent in real time.

Receive alerts on INPI events, decisions, and expiry dates for your portfolio.